Molecular and cellular heterogeneity: The hallmark of glioblastoma

Neurosurgical Focus

Volumn 37, Issue 6, 2014, Pages

  Aum, Diane J ^a   Kim, David H ^a   Beaumont, Thomas L ^a   Leuthardt, Eric C ^a,b   Dunn, Gavin P ^a,b   Kim, Albert H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

Genomic; Glioblastoma; Glioma; Heterogeneity; IDH1

Indexed keywords

BRAIN TUMOR; GENETIC VARIABILITY; GENETICS; GLIOBLASTOMA; HUMAN; PATHOLOGY;

BRAIN NEOPLASMS; GENETIC VARIATION; GLIOBLASTOMA; HUMANS;

EID: 84916925411     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.9.FOCUS14521     Document Type: Article

References (69)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
2. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al: Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 123:3659-3663, 2013
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006
4. Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, et al: Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 21:11-24, 2012
5. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al: IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81-91, 2014
6. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al: Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104:20007-20012, 2007
7. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al: Mesenchymal differentiation mediated by NF-kB promotes radiation resistance in glioblastoma. Cancer Cell 24:331-346, 2013
8. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4:226-235, 2009
9. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, et al: A network model of a cooperative genetic landscape in brain tumors. JAMA 302:261-275, 2009
10. Brennan C: Genomic profiles of glioma. Curr Neurol Neurosci Rep 11:291-297, 2011
11. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
12. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-1113, 2010
13. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
14. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al: Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349-1355, 2012
15. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-526, 2012
16. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al: A hierarchy of self-renewing tumorinitiating cell types in glioblastoma. Cancer Cell 17:362-375, 2010
17. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al: Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139-152, 2013
18. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al: The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463-469, 2011
19. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al: A multigene predictor of outcome in glioblastoma. Neuro Oncol 12:49-57, 2010
20. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009
21. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506-510, 2012
22. Dunn GP, Andronesi OC, Cahill DP: From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus 34(2):E2, 2013
23. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, et al: Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26:756-784, 2012
24. Francis JM, Zhang CZ, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, et al: EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 4:956-971, 2014
25. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
26. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537, 1999
27. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al: The mutational landscape of lethal castrationresistant prostate cancer. Nature 487:239-243, 2012
28. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718, 2010
29. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474, 2009
30. Huse JT, Phillips HS, Brennan CW: Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 59:1190-1199, 2011
31. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al: Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24:1731-1745, 2010
32. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ: Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev 45:143-163, 2004
33. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al: Mutational analysis reveals the origin and therapydriven evolution of recurrent glioma. Science 343:189-193, 2014
34. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021-6026, 2013
35. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al: Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484-488, 2012
36. Kreso A, Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell 14:275-291, 2014
37. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al: Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482-4490, 2011
38. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, et al: Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6:421-432, 2010
39. Lathia JD, Heddleston JM, Venere M, Rich JN: Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 8:482-485, 2011
40. McDermott U, Downing JR, Stratton MR: Genomics and the continuum of cancer care. N Engl J Med 364:340-350, 2011
41. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G: GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41, 2011
42. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al: Tumour evolution inferred by single-cell sequencing. Nature 472:90-94, 2011
43. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M: Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 21:53-56, 2004
44. Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al: Medulloblastomics: the end of the beginning. Nat Rev Cancer 12:818-834, 2012
45. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al: The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16:896-913, 2014
46. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
47. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396-1401, 2014
48. Patmore HS, Ashman JN, Stafford ND, Berrieman HK, Mac-Donald A, Greenman J, et al: Genetic analysis of head and neck squamous cell carcinoma using comparative genomic hybridisation identifies specific aberrations associated with laryngeal origin. Cancer Lett 258:55-62, 2007
49. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006
50. Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, et al: A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of aHG. Biochemistry 50:4804-4812, 2011
51. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824-828, 2010
52. Riddick G, Fine HA: Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 7:439-450, 2011
53. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004
54. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-817, 2011
55. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 108:4274-4280, 2011
56. Son MJ, Woolard K, Nam DH, Lee J, Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4:440-452, 2009
57. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290, 2007
58. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
59. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, et al: Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92-107, 2014
60. Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, et al: Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580-594, 2014
61. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al: Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 109:3041-3046, 2012
62. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-483, 2012
63. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
64. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al: Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829-833, 2010
65. Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, et al: Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 13:355-364, 2008
66. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, et al: Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482:529-533, 2012
67. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30, 2011
68. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117, 2010
69. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009